Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes User prevmedmod, in the PrevMed subreddit, 13 Mar 2024
Novo Nordisk study finds that semaglutide (Wegovy) reduces risk of serious cardiovascular events such as heart attacks by 20% in overweight patients with a history of cardiovascular disease and no history of diabetes User worldnewsbot, in the News From Around The World subreddit, 11 Nov 2023
Novo Nordisk study finds that semaglutide (Wegovy) reduces risk of serious cardiovascular events such as heart attacks by 20% in overweight patients with a history of cardiovascular disease and no history of diabetes User maximum_cats, in the Reddit Science subreddit, 11 Nov 2023